Advertisement


Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

First International Summit on Interventional Pharmacoeconomics

Advertisement

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.



Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Advertisement

Advertisement




Advertisement